Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab U.S.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Efficacy and safety were evaluated in EPCORE NHL-1 (Study GCT3013-01; ClinicalTrials.gov. Identifier: NCT03625037), an open-label, multi-cohort,